What you get by completing this session

  • 35 mins of CPD

    A 25 minute video lecture with presentation slides, you can stop and start anytime you like. 10 minute quiz is included.

  • Certificate of Completion

    Receive a certificate once you complete the session. Download this from your student dashboard or in your course completion email

  • Easy CPD Documentation

    Fill out the CPD Documentation activity at the end of the session, receive a PDF summary of your CPD activity and reflection right to your email inbox to save or print out!

What you'll learn in this expert session

Keratinocyte cancer (KC) is more common than all other forms of cancer, combined. Australia is particularly vulnerable and has the highest rate in the world. Extensive sun exposure and increasing age are the primary risk factors. Patients also tend to develop multiple lesions, which can be particularly burdensome. Emerging treatments, such as widefield radiation therapy, can target large areas of both cancer and pre-cancerous lesions with the goal of reducing the need for frequent interventions. This option holds promise for patients with severe disease who have exhausted other therapeutic options.

About the Expert

Dr Ian Porter

Dr Ian Porter is the Director of Radiation Oncology at Cabrini Health and is based at GenesisCare Cabrini in Melbourne, Australia. He is also a trials investigator with TROG and the NHMRC, with special interests in skin, gastrointestinal, lung and haematological malignancies. His other interests include stereotactic radiotherapy. He was the first Radiation Oncologist in Australasia to use Brainlab gated stereotactic radiotherapy for treatment of liver tumours.

Course curriculum

  • 1

    How to complete this course

    • Instructions

  • 2

    Emerging Treatments for Skin Cancer and Post Treatment Care

    • Summary and learning objectives

    • Video lecture (25 mins)

    • Quiz: test your learning (10 mins)

  • 3

    Document your CPD here

    • CPD Documentation and Reflection Activity Tool

  • 4


    • Please let us know your thoughts